Welcome to our dedicated page for Alpha Cognition news (Ticker: ACOG), a resource for investors and traders seeking the latest updates and insights on Alpha Cognition stock.
Alpha Cognition Inc. (NASDAQ: ACOG) is a commercial-stage biopharmaceutical company focused on neurodegenerative diseases, particularly Alzheimer’s disease and cognitive impairment associated with mild traumatic brain injury (mTBI). The Alpha Cognition news feed on Stock Titan aggregates company announcements, clinical updates, and capital markets disclosures so readers can follow how its Alzheimer’s and neuroscience programs progress over time.
News for ACOG frequently centers on the commercialization of ZUNVEYL, an FDA-approved new-generation acetylcholinesterase inhibitor for mild to moderate Alzheimer’s dementia in adults. Company releases describe launch momentum in the U.S. long-term care channel, including growth in pharmacy orders, expansion of the prescriber base, and increasing penetration into nursing homes. Updates also cover payer coverage developments, such as additional pharmacy benefit manager contracts, and the company’s efforts to deepen relationships with long-term care facilities.
Investors and healthcare observers will also find coverage of clinical and real-world evidence studies involving ZUNVEYL and ALPHA-1062, including planned and ongoing studies in Alzheimer’s disease patients in long-term care settings and research on cognitive impairment following traumatic brain injury. Alpha Cognition regularly reports on scientific presentations at meetings like the American Society of Consultant Pharmacists and the Neuroscience Education Institute, where it shares data on cholinesterase inhibitors, treatment persistence, and patient outcomes.
In addition, the ACOG news stream includes financing transactions, such as public offerings and at-the-market programs, licensing agreements for ZUNVEYL in Asia, and SEC-reportable events like changes in auditors or stock incentive plans. By reviewing this page, readers can track how Alpha Cognition’s commercial execution, clinical data, and corporate actions evolve, all in one consolidated news hub.
Alpha Cognition (NASDAQ: ACOG) outlined 2026 priorities to scale commercialization of ZUNVEYL, targeting ~2,000 prescribing healthcare providers and deeper nursing home penetration. The company expects payor coverage expansion via additional PBM contracts in 2026, plans three ZUNVEYL studies (CONVERGE ~400-patient retrospective, BEACON real-world effectiveness, RESOLVE phase 4), and anticipates multiple ex-US country approvals and a conditional $3 million licensing milestone in Q1. 2025 milestones included a $44 million exclusive Asia licensing deal, China NDA acceptance for CMS, a $40 million capital raise, patent protection through 2044, and ~600 HCPs with >500 nursing homes prescribing by Q3 2025.
Alpha Cognition (Nasdaq: ACOG) will participate in a virtual fireside chat hosted by Titan Partners to discuss commercialization efforts and research initiatives aimed at accelerating commercial adoption.
Event details: Titan Partners Fireside Chat on December 2, 2025, 12:00 pm–1:00 pm ET; participant Michael McFadden, CEO; host Boris Peaker, Managing Director, Titan Partners. Registration is available via the provided webinar link.
Alpha Cognition (NASDAQ: ACOG) reported accelerating 3Q25 commercialization of ZUNVEYL, driven by expansion in the U.S. long-term care channel. Pharmacy orders grew 102% sequentially, prescription volumes hit record monthly highs, and reach extended to >600 nursing homes with a prescriber base above 500 clinicians. Revenue for the quarter was $2.8M, comprising $2.3M of ZUNVEYL net product sales and $0.5M of licensing revenue. Pro forma cash after an October equity raise is about $73.2M, with a $75M ATM facility and roughly two years of runway at planned operating spend. Management continues to prioritize an LTC-focused call strategy to drive durable adoption and repeat ordering.
Alpha Cognition (Nasdaq: ACOG) reported Q3 2025 results and operational progress for ZUNVEYL on November 13, 2025. The company recorded $2.8 million in total revenue for the quarter, including $2.3 million in product sales and $0.5 million in licensing revenue. Pharmacy orders rose 102% quarter-over-quarter and prescribers exceeded 500 (55% growth QoQ). Q3 operating expenses were $7.5 million, operating loss was $5.3 million, and net loss improved to $1.3 million. Cash was $35.4 million at Sept 30, 2025, with an October capital raise adding $37.8 million net for ~$73.2 million pro forma cash and an estimated ~two-year runway at forecasted levels.
Alpha Cognition (Nasdaq: ACOG) will report its third quarter 2025 financial results and provide a business update on Thursday, November 13, 2025 at 4:30 p.m. ET after market close.
The company will publish a press release and supporting materials on its investor news page and host a live conference call and webcast following the release; a replay will be available via dial-in and webcast.
Alpha Cognition (Nasdaq: ACOG) will present new clinical data on cholinesterase inhibitors and ZUNVEYL® (benzgalantamine) at two scientific meetings in late 2025. The company will present poster sessions at the ASCP Annual Meeting (Oct 23–25, 2025) and the NEI Annual Congress (Nov 6–9, 2025).
Accepted posters cover AChEI topics including persistence of therapy, switching methodologies, interactions with psychotropic medications, and literature reviews on effects on mortality and sleep in Alzheimer’s disease and related dementias.
The company says ZUNVEYL is an enteric-coated prodrug designed to combine cholinesterase inhibition with nicotinic receptor modulation to improve treatment continuity.
Alpha Cognition (Nasdaq: ACOG) will present new clinical data at the American Society of Consultant Pharmacists (ASCP) Annual Meeting, October 23–25, 2025.
On October 24, 2025 the company will present three posters: Poster 12 — Acetylcholinesterase Inhibitors and Psychotropic Medication Use in ADRD; Poster 3 — Persistence of Therapy in ADRD; and Poster 4 — Evidence-Based Approaches to Switching AChEIs in Alzheimer’s Disease. Presentations include insights on cholinesterase inhibitors and ZUNVEYL (benzgalantamine) aimed at updating evidence-based guidance for clinicians treating older adults with neurodegenerative disease.
Alpha Cognition (Nasdaq: ACOG) has announced the pricing of its oversubscribed public offering of 5.6 million common shares at $6.25 per share, raising approximately $35 million in gross proceeds. The offering includes a 30-day over-allotment option for an additional 840,000 shares.
The company's total cash position is expected to reach $70 million post-closing. The proceeds will fund the commercial launch acceleration of ZUNVEYL® (Benzgalantamine), focusing on sales expansion, marketing investment, and enhancing payer coverage and reimbursement infrastructure in the Alzheimer's treatment market.
The offering, led by Titan Partners Group, is expected to close around October 2, 2025, with strong participation from both existing shareholders and a premier healthcare-dedicated investor.
Alpha Cognition (NASDAQ:ACOG), a commercial-stage biopharmaceutical company focused on neurodegenerative diseases, has announced a proposed underwritten public offering of common shares and pre-funded warrants. The company will grant underwriters a 30-day option to purchase up to 15% additional common shares.
The net proceeds will be used to accelerate commercial launch activities, including sales expansion, marketing investment, and enhancing payer coverage infrastructure in the Alzheimer's treatment landscape. Titan Partners Group is acting as the sole bookrunner for this offering, which will be made under the company's effective S-3 shelf registration.
Alpha Cognition (Nasdaq: ACOG), a commercial-stage biopharmaceutical company focused on neurodegenerative disease treatments, has announced its upcoming participation in two major healthcare investor conferences in September 2025.
CEO Michael McFadden will present at the Cantor Global Healthcare Conference on September 5 at 7:00 a.m. ET and the H.C. Wainwright & Co. Healthcare Conference on September 9 at 2:00 p.m. ET. Presentation transcripts will be available on the company's website for 30 days following the events.
FAQ
What is the current stock price of Alpha Cognition (ACOG)?
What is the market cap of Alpha Cognition (ACOG)?
